Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo

Status Recruiting

Clinical Trial Summary

Pancreatic carcinoma patients got benefit from adjuvant therapy after radical surgery. Gemcitabine combined with albumin-paclitaxel was recommended as the first-line regimen for adjuvant chemotherapy by NCCN guidelines. The most common non-hematological adverse events associated with gemcitabine combined with albumin-paclitaxel treatment were fatigue (54%), followed by alopecia (50%), and grade 3 or higher adverse events were mainly granulocytopenia, leukopenia, fatigue, and peripheral nerve damage. Cancer-related fatigue (CRF) is the most common concomitant symptom in cancer patients, especially during chemotherapy, which has a negative impact on patients' work, social relationships, emotions and daily activities. Therefore, it is of great clinical significance to improve CRF in cancer patients. From the perspective of traditional Chinese medicine, CRF patients will have a series of syndromes such as low function of viscera, general weakness, and emaciation, which last for more than 2 weeks and affect patients' physiology and psychology at the same time. Codonopsis pilosula Nnannf can restore the postoperative immune ability of patients as soon as possible after chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05613465
Study type	Interventional
Source	Zhejiang Provincial People's Hospital
Contact	tao xia
Phone	+8618653268208
Email	taoxiamd@hotmail.com
Status	Recruiting
Phase	N/A
Start date	October 25, 2022
Completion date	December 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05497531` - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	N/A
Recruiting	`NCT05237193` - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Active, not recruiting	`NCT04602026` - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer	N/A
Completed	`NCT03645148` - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer	Phase 1
Recruiting	`NCT02587689` - Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor	Phase 1/Phase 2
Active, not recruiting	`NCT02676349` - Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)	Phase 2
Active, not recruiting	`NCT03267524` - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers	N/A
Recruiting	`NCT04147494` - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues	Early Phase 1
Recruiting	`NCT05642962` - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1/Phase 2
Active, not recruiting	`NCT03164486` - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide	Early Phase 1
Active, not recruiting	`NCT02009449` - A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors	Phase 1
Terminated	`NCT03137706` - Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
Not yet recruiting	`NCT06080854` - AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer	Phase 2
Completed	`NCT03962478` - Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction	N/A
Completed	`NCT03849469` - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors	Phase 1
Terminated	`NCT00907166` - A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients	Phase 1/Phase 2
Not yet recruiting	`NCT06271291` - Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Active, not recruiting	`NCT03752398` - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)	Phase 1
Completed	`NCT03949933` - Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer	N/A
Recruiting	`NCT03711890` - Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer	N/A